VANDERBILT UNIVERSITY MEDICAL CENTER

Type: Teaching hospital
Where: NASHVILLE, TN
Medicare CCN: 440039
Received: $25,961,318 in 3,129 records, 2019 ($1,154,464 general, $24,806,853 research)
Source: CMS Open Payments search ↗

On this site

Business registration: Vanderbilt University Medical Center Fuzzy (name and state)
Business registration: Vanderbilt University Medical Center Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER, INC. Fuzzy (name and state)
Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER, INC. Fuzzy (name and state)
Nonprofit contractor: Vanderbilt University Medical Center Fuzzy (name and state)
Plan sponsor: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Federal award recipient: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Lobbying client: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Lobbying registrant: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Nonprofit: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
Trademark owner: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2019	General payment	278	$1,154,464
2019	Research payment	2,851	$24,806,853

By company

Company	Records	Amount	Years
PFIZER INC.	124	$2,095,418	2019
ABBVIE INC.	213	$1,980,852	2019
Genentech, Inc.	94	$1,787,846	2019
Merck Sharp & Dohme LLC	278	$1,775,441	2019
Shire North American Group Inc	119	$1,285,258	2019
CSL Behring	31	$961,828	2019
E.R. Squibb & Sons, L.L.C.	49	$888,505	2019
Gilead Sciences, Inc.	162	$732,781	2019
Abbott Laboratories	36	$674,771	2019
GE HEALTHCARE	17	$650,566	2019
Amgen Inc.	18	$630,109	2019
Novo Nordisk AS	325	$551,862	2019
Medtronic Vascular, Inc.	73	$530,276	2019
BioMarin Pharmaceutical Inc.	63	$522,614	2019
Cumberland Pharmaceuticals, Inc.	26	$441,811	2019
Janssen Research & Development, LLC	59	$429,691	2019
Bayer Healthcare Pharmaceuticals Inc.	121	$403,050	2019
Regeneron Pharmaceuticals, Inc.	34	$383,544	2019
Ultragenyx Pharmaceutical Inc.	21	$356,991	2019
Biogen, Inc.	7	$339,691	2019
Agios Pharmaceuticals, Inc.	29	$321,906	2019
F. Hoffmann-La Roche AG	12	$311,959	2019
Advanced Bionics, LLC	7	$308,736	2019
Roche TCRC, Inc.	22	$308,164	2019
Kadmon Corporation LLC	4	$302,571	2019
Edwards Lifesciences Corporation	7	$301,479	2019
EMD Serono, Inc.	44	$284,086	2019
Stryker Corporation	13	$282,866	2019
SEAGEN INC.	21	$272,078	2019
Allergan, Inc.	30	$252,443	2019
Pharmacyclics LLC, an AbbVie Company	60	$249,532	2019
Mallinckrodt Enterprises LLC	30	$237,324	2019
Kite Pharma, Inc.	34	$217,731	2019
Boehringer Ingelheim Pharmaceuticals, Inc.	8	$192,581	2019
Intercept Pharmaceuticals, Inc.	30	$186,663	2019
Novo Nordisk Inc	3	$179,880	2019
Soleno Therapeutics, Inc.	1	$171,247	2019
Boston Scientific Corporation	36	$166,893	2019
SANOFI PASTEUR INC.	3	$159,415	2019
JAZZ PHARMACEUTICALS INC.	13	$155,415	2019
Ortho-Clinical Diagnostics, Inc.	1	$151,303	2019
Medtronic USA, Inc.	5	$142,232	2019
Medtronic, Inc.	20	$141,306	2019
AstraZeneca Pharmaceuticals LP	20	$129,916	2019
SANOFI US SERVICES INC.	8	$129,611	2019
AXOGEN	9	$125,128	2019
Cerus Corporation	7	$119,353	2019
Alnylam Pharmaceuticals Inc.	9	$116,616	2019
Novartis Pharmaceuticals Corporation	9	$113,124	2019
Alexion Pharmaceuticals, Inc.	179	$111,546	2019

By nature of payment

Nature	Records	Amount
Research payment	2,851	$24,806,853
Grant	69	$730,185
Space rental or facility fees (teaching hospital only)	94	$185,744
Education	16	$101,310
Royalty or License	54	$46,218
Gift	19	$33,390
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	16	$29,615
Charitable Contribution	4	$15,440
Honoraria	1	$8,500
Consulting Fee	1	$2,000
Entertainment	1	$1,750
Food and Beverage	3	$310

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2019-12-31	JAZZ PHARMACEUTICALS INC.	$129,816	Research payment	In-kind items and services	DEFITELIO Drug, HEMATOLOGY	A PHASE 3, RANDOMIZED, ADAPTIVE STUDY COMPARING THE EFFICACY AND SAFETY OF DEFIBROTIDE VS BEST SUPPORTIVE CARE IN THE PR	2019
2019-12-31	Ultragenyx Pharmaceutical Inc.	$101,702	Research payment	Cash or cash equivalent		UX007-CL202	2019
2019-12-31	Haemonetics Corporation	$11,250	Research payment	In-kind items and services	TEG Device, Devices	INSIGHT-The illumaniting neurophyschological dysfunction and systematic inflammatory mechanisms gleaned after hospitaliz	2019
2019-12-31	Roche Diagnostics Operations, Inc.	$10,965	Research payment	Cash or cash equivalent	CD cobas Reagents Device, Centralized Diagnostics	RD005090	2019
2019-12-31	Allergan, Inc.	$9,007	Research payment	Cash or cash equivalent		A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had	2019
2019-12-31	Merck Sharp & Dohme LLC	$8,570	Research payment	Cash or cash equivalent	ZINPLAVA Biological, INFECTIOUS DISEASE	Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar	2019
2019-12-31	Endogastric Solutions, Inc	$7,500	Research payment	Cash or cash equivalent	EsophyX Device, GERD		2019
2019-12-31	Merck Sharp & Dohme LLC	$4,740	Research payment	Cash or cash equivalent	ZINPLAVA Biological, INFECTIOUS DISEASE	Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar	2019
2019-12-31	Roche Diagnostics Operations, Inc.	$2,818	Research payment	In-kind items and services	CD cobas Reagents Device, Centralized Diagnostics	RD005090	2019
2019-12-31	Ultragenyx Pharmaceutical Inc.	$2,755	Research payment	Cash or cash equivalent		UX023-CL301	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$2,476	Research payment	In-kind items and services		A Multi arm Phase Ib Open Label, Multicentre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary An	2019
2019-12-31	bioMerieux Inc	$2,452	Research payment	In-kind items and services	VIDAS BRAHMS PCT Device, Diagnostic	Pneumonia Severity in Children: Reducing Variation in Management Through Analysis of Admission Predictors and Procalcito	2019
2019-12-31	BioMarin Pharmaceutical Inc.	$1,395	Research payment	Cash or cash equivalent		A Prospective Non-Interventional Study of Bleeding Episodes, Factor VIII Infusions, and Patient-Reported Outcomes in Ind	2019
2019-12-31	AstraZeneca UK Limited	$507	Research payment	In-kind items and services	IMFINZI Drug, Oncology	This is a randomized open label multi center global Phase III study to determine the efficacy and safety of MEDI4736 as	2019
2019-12-31	Agilent Technologies, Inc.	$440	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-12-31	AstraZeneca UK Limited	$335	Research payment	In-kind items and services	IMFINZI Drug, Oncology	A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squa	2019
2019-12-31	AstraZeneca UK Limited	$317	Research payment	In-kind items and services	BYDUREON Drug, Cardiovascular and Metabolism	A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$181	Research payment	In-kind items and services	FARXIGA Drug, Cardiovascular and Metabolism	A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$150	Research payment	In-kind items and services		A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumou	2019
2019-12-31	Stryker Corporation	$150	Gift	In-kind items and services	PRIME ELECTRIC W/ ZOOM Device, PATIENT HANDLING - PH		2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$122	Research payment	In-kind items and services	FARXIGA Drug, Cardiovascular and Metabolism	Forxiga HF-D1699C00001 HF rEF Outcome study	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$81	Research payment	In-kind items and services		A Modular Phase I Open-Label Multicentre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Anti-t	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$38	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	Study of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration Resistant Prosta	2019
2019-12-31	AstraZeneca Pharmaceuticals LP	$21	Research payment	In-kind items and services	TAGRISSO Drug, Oncology	A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumou	2019
2019-12-30	TransMedics, Inc.	$8,509	Research payment	Cash or cash equivalent	Organ Care System Device, Device	HEART EXPAND CAP	2019
2019-12-30	ABBVIE INC.	$1,144	Research payment	Cash or cash equivalent	Skyrizi Biological, Immunology	M16-000	2019
2019-12-27	E.R. Squibb & Sons, L.L.C.	$2,041	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III RCC Monotherapy vs. everolimus ONO 4538-03	2019
2019-12-27	BONE SUPPORT AB	$1,700	Research payment	Cash or cash equivalent	CERAMENT G Device, Bone void and fracture	A Prospective, Randomized Multicenter Controlled Trial of CERAMENT G as Part of Surgical Repair of Open Diaphyseal Tibia	2019
2019-12-26	United Therapeutics Corporation	$3,509	Research payment	Cash or cash equivalent	ORENITRAM Drug, PAH	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ORAL TREPROSTIN	2019
2019-12-26	United Therapeutics Corporation	$2,909	Research payment	Cash or cash equivalent	ORENITRAM Drug, PAH	AN OPEN-LABEL EXTENSION STUDY OF ORAL TREPROSTINIL IN SUBJECTS WITH PULMONARY HYPERTENSION PH ASSOCIATED WITH HEART FAIL	2019
2019-12-26	ABBVIE INC.	$2,000	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-430	2019
2019-12-26	ARRAY BIOPHARMA INC	$1,145	Research payment	Cash or cash equivalent	Braftovi Drug, Melanoma	818-302	2019
2019-12-25	Amgen Inc.	$1,399	Research payment	Cash or cash equivalent		GALACTIC-HF	2019
2019-12-24	Amgen Inc.	$32,408	Research payment	Cash or cash equivalent		AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543.	2019
2019-12-23	Janssen Research & Development, LLC	$49,377	Research payment	Cash or cash equivalent		Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib	2019
2019-12-23	ABBVIE INC.	$26,701	Research payment	Cash or cash equivalent		M15-570	2019
2019-12-23	Janssen Research & Development, LLC	$12,134	Research payment	Cash or cash equivalent		Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib	2019
2019-12-23	Ethicon Endo-Surgery Inc.	$5,094	Research payment	Cash or cash equivalent	ECHELON FLEX Stapler Device, Endo-Mechanical	A Videographic Study to Evaluate the Impact of a Pulsed Firing Technique on Staple Line Interventions in Laparoscopic Sl	2019
2019-12-23	BioMarin Pharmaceutical Inc.	$4,858	Research payment	Cash or cash equivalent		Multicenter multinational study to collect consistent baseline growth measurements on pediatric patients with Achondropl	2019
2019-12-23	Janssen Research & Development, LLC	$3,459	Research payment	Cash or cash equivalent		Optimizing Post-Allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma using Ibrutinib	2019
2019-12-23	Janssen Research & Development, LLC	$1,089	Research payment	Cash or cash equivalent		Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez	2019
2019-12-23	Plexxikon Inc.	$1,000	Research payment	Cash or cash equivalent		Safety Study of PLX108-01 in Patients With Solid Tumors	2019
2019-12-20	INSTRUMENTATION LABORATORY COMPANY	$31,634	Research payment	Cash or cash equivalent	Pre-Clinical Device		2019
2019-12-20	ACADIA Pharmaceuticals Inc	$18,174	Research payment	Cash or cash equivalent		2566-004	2019
2019-12-20	ACADIA Pharmaceuticals Inc	$18,174	Research payment	Cash or cash equivalent		2566-003	2019
2019-12-20	Cerus Corporation	$10,457	Research payment	Cash or cash equivalent	INTERCEPT Device, DEVICE-TRANSFUSION	CLI00112 - PIPER	2019
2019-12-20	ABBVIE INC.	$4,696	Research payment	Cash or cash equivalent	Skyrizi Biological, Immunology	M16-067	2019
2019-12-20	MED-EL Corporation	$4,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	MED-EL Maestro Cochlear Implant System Device, Cochlear Implant		2019
2019-12-20	W. L. Gore & Associates, Inc.	$3,100	Research payment	Cash or cash equivalent	Product in Development Device, Devices	Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms	2019
2019-12-20	GE HEALTHCARE	$2,091	Research payment	Cash or cash equivalent		A PHASE 3 OPEN LABEL MULTICENTRE STUDY OF FLURPIRIDAZ (18F) INJECTION FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR	2019
2019-12-20	Medical Device Business Services, Inc.	$1,500	Research payment	Cash or cash equivalent		Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptoma	2019
2019-12-19	Daiichi Sankyo Company LTD	$23,077	Research payment	Cash or cash equivalent	Enhertu Drug, Oncology	DS8201-A-J203	2019
2019-12-19	F. Hoffmann-La Roche AG	$15,566	Research payment	Cash or cash equivalent	Drug	V1A 2 IN PEDIATRIC AUTISM	2019
2019-12-19	PFIZER INC.	$10,956	Research payment	Cash or cash equivalent	VYNDAQEL Drug, CARDIOVASCULAR	A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS ME	2019
2019-12-19	Intercept Pharmaceuticals, Inc.	$9,216	Research payment	Cash or cash equivalent		1009742	2019
2019-12-19	BioMarin Pharmaceutical Inc.	$8,792	Research payment	Cash or cash equivalent		A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in	2019
2019-12-19	PFIZER INC.	$6,095	Research payment	Cash or cash equivalent		FIP STUDY FOR PRMT5	2019
2019-12-19	Janssen Research & Development, LLC	$4,762	Research payment	Cash or cash equivalent		A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for th	2019
2019-12-19	Novo Nordisk AS	$3,000	Research payment	Cash or cash equivalent		NN9536-4373	2019
2019-12-19	Chiesi USA, Inc.	$2,000	Grant	Cash or cash equivalent	CUROSURF Drug, NEONATOLOGY		2019
2019-12-19	Janssen Research & Development, LLC	$1,609	Research payment	Cash or cash equivalent		Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez	2019
2019-12-19	Novo Nordisk AS	$1,580	Research payment	Cash or cash equivalent		NN9536-4374	2019
2019-12-19	ABBVIE INC.	$1,500	Research payment	Cash or cash equivalent	Skyrizi Biological, Immunology	M16-000	2019
2019-12-19	Agios Pharmaceuticals, Inc.	$1,437	Research payment	Cash or cash equivalent	TIBSOVO Drug, ONCOLOGY	STUDY OF AG-120 IN PREVIOUSLY TREATED ADVANCED CHOLANGIOCARCINOMA WITH IDH1 MUTATIONS CLARIDHY	2019
2019-12-19	Novo Nordisk AS	$1,368	Research payment	Cash or cash equivalent		NN9536-4373	2019
2019-12-19	TransMedics, Inc.	$575	Research payment	Cash or cash equivalent	Organ Care System Device, Device	HEART EXPAND CAP	2019
2019-12-18	Gilead Sciences, Inc.	$19,600	Research payment	Cash or cash equivalent		A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL	2019
2019-12-18	Abbott Laboratories	$13,500	Research payment	Cash or cash equivalent	Vysis MultiVysion Probes Device, Molecular Diagnostics	Clinical Relevance of PTEN and ERG Chromosomal Alterations in Men with Localized Prostate Cancer	2019
2019-12-18	Gilead Sciences, Inc.	$2,253	Research payment	Cash or cash equivalent		A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL	2019
2019-12-18	Gilead Sciences, Inc.	$2,063	Research payment	Cash or cash equivalent		A Phase 2, Double-blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Tr	2019
2019-12-18	Gilead Sciences, Inc.	$1,623	Research payment	Cash or cash equivalent		A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis	2019
2019-12-18	Gilead Sciences, Inc.	$1,367	Research payment	Cash or cash equivalent		A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory C	2019
2019-12-18	Gilead Sciences, Inc.	$1,218	Research payment	Cash or cash equivalent		Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib	2019
2019-12-18	Gilead Sciences, Inc.	$1,182	Research payment	Cash or cash equivalent		A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease	2019
2019-12-18	KLS-Martin L.P.	$500	Grant	Cash or cash equivalent			2019
2019-12-18	Gilead Sciences, Inc.	$500	Research payment	Cash or cash equivalent		A Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in high risk 1st Line DLBCL	2019
2019-12-18	Medtronic, Inc.	$250	Research payment	Cash or cash equivalent	SYNCHROMED Device, Drug Infusion Systems	PSR-TDD	2019
2019-12-18	Medtronic, Inc.	$250	Research payment	Cash or cash equivalent	ACTIVA Device, Deep Brain Neurostimulation	PSR-DBS	2019
2019-12-18	Novo Nordisk AS	$245	Research payment	Cash or cash equivalent		NN7415-4255	2019
2019-12-18	Novo Nordisk AS	$143	Research payment	Cash or cash equivalent		NN7415-4255	2019
2019-12-18	Gilead Sciences, Inc.	$27	Research payment	Cash or cash equivalent		A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof	2019
2019-12-17	EMD Serono, Inc.	$58,159	Research payment	Cash or cash equivalent	MSC2490484A Biological, Oncology	MS201964-0001	2019
2019-12-17	Genentech, Inc.	$13,812	Research payment	Cash or cash equivalent	Drug	TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS	2019
2019-12-17	Genentech, Inc.	$13,459	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	ASO HTT PIVOTAL TRIAL	2019
2019-12-17	Genentech, Inc.	$13,000	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE III STUDY OF BALOVAPTAN IN ADULTS WITH ASD	2019
2019-12-17	BioMarin Pharmaceutical Inc.	$9,086	Research payment	Cash or cash equivalent		A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop	2019
2019-12-17	Allergan, Inc.	$6,078	Research payment	Cash or cash equivalent		AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of	2019
2019-12-17	Shire North American Group Inc	$1,500	Research payment	Cash or cash equivalent		STUDY OF THE EFFECT OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO AC	2019
2019-12-17	Merck Sharp & Dohme LLC	$1,302	Research payment	In-kind items and services	PNEUMOVAX 23 Biological, VACCINE	Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes. The PNEUMO Study	2019
2019-12-17	Roche Products Limited	$1,145	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY	2019
2019-12-17	Merck Sharp & Dohme LLC	$775	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand	2019
2019-12-16	Merck Sharp & Dohme LLC	$17,000	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot	2019
2019-12-16	Edwards Lifesciences Corporation	$15,787	Research payment	Cash or cash equivalent		Early-TAVR Trial 2016-07	2019
2019-12-16	EMD Serono, Inc.	$3,339	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-16	Janssen Research & Development, LLC	$2,257	Research payment	Cash or cash equivalent		Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez	2019
2019-12-16	EMD Serono, Inc.	$1,613	Research payment	Cash or cash equivalent	EMD 1214063 Biological, Oncology	MS200095-0022	2019
2019-12-16	KARL STORZ Endoscopy-America	$1,500	Grant	Cash or cash equivalent	URETERO-RENOSCOPE, 7FR X 34CM, ACLAV Device, UROLOGY		2019
2019-12-16	SWEDISH ORPHAN BIOVITRUM AB	$1,500	Research payment	Cash or cash equivalent	KINERET Drug, INFLAMMATION	SOBI.ANAKIN-301	2019
2019-12-16	Gilead Sciences, Inc.	$1,500	Research payment	Cash or cash equivalent		A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis	2019
2019-12-16	Gilead Sciences, Inc.	$1,500	Research payment	Cash or cash equivalent		Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgoti	2019
2019-12-16	Boston Scientific Corporation	$1,500	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	PREEMPT HF	2019
2019-12-16	Allergan, Inc.	$1,308	Research payment	Cash or cash equivalent		A multicenter, open-label, single arm study in patients with open angle glaucoma or ocular hypertension who have not had	2019
2019-12-16	Boston Scientific Corporation	$374	Research payment	Cash or cash equivalent	CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT	PREEMPT HF	2019
2019-12-15	Novo Nordisk AS	$665	Research payment	Cash or cash equivalent		NN7415-4255	2019
2019-12-13	Allergan, Inc.	$10,000	Research payment	Cash or cash equivalent		Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato	2019
2019-12-13	Allergan, Inc.	$3,000	Research payment	Cash or cash equivalent		Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato	2019
2019-12-13	Allergan, Inc.	$1,935	Research payment	Cash or cash equivalent		Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato	2019
2019-12-13	Allergan, Inc.	$750	Research payment	Cash or cash equivalent		Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	Shire North American Group Inc	$677	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-13	SOBI, INC	$600	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	SYNAGIS Drug, Immunology		2019
2019-12-13	Pharmacyclics LLC, an AbbVie Company	$485	Research payment	Cash or cash equivalent	Ibrutinib Drug, Oncology	PCYC-1145-LT	2019
2019-12-13	Pharmacyclics LLC, an AbbVie Company	$485	Research payment	Cash or cash equivalent	Ibrutinib Drug, Oncology	PCYC-1145-LT	2019
2019-12-13	Pharmacyclics LLC, an AbbVie Company	$485	Research payment	Cash or cash equivalent	Ibrutinib Drug, Oncology	PCYC-1145-LT	2019
2019-12-13	Allergan, Inc.	$400	Research payment	Cash or cash equivalent		Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steato	2019
2019-12-13	Shire North American Group Inc	$135	Research payment	Cash or cash equivalent	GATTEX Drug, INTERNAL MEDICINE	A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME	2019
2019-12-12	Roche TCRC, Inc.	$52,110	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS	2019
2019-12-12	GlaxoSmithKline, LLC.	$19,809	Research payment	Cash or cash equivalent			2019
2019-12-12	PFIZER INC.	$15,007	Research payment	Cash or cash equivalent		PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN	2019
2019-12-12	PFIZER INC.	$4,605	Research payment	Cash or cash equivalent		PHASE 1B STUDY TO ASSESS THE SAFETY TOLERABILITY AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AN	2019
2019-12-12	BioMarin Pharmaceutical Inc.	$3,379	Research payment	Cash or cash equivalent	Palynziq Drug, PKU	An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/day	2019
2019-12-12	BioMarin Pharmaceutical Inc.	$3,081	Research payment	Cash or cash equivalent		A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop	2019
2019-12-12	Bayer Healthcare Pharmaceuticals Inc.	$2,585	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-12	Intercept Pharmaceuticals, Inc.	$1,613	Research payment	Cash or cash equivalent		1009742	2019
2019-12-12	ABBVIE INC.	$1,500	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-675	2019
2019-12-12	Bayer Healthcare Pharmaceuticals Inc.	$1,162	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-12	Roche TCRC, Inc.	$991	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS	2019
2019-12-12	Bayer Healthcare Pharmaceuticals Inc.	$750	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-12	Bayer Healthcare Pharmaceuticals Inc.	$500	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-12	Roche TCRC, Inc.	$439	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS	2019
2019-12-12	Bayer Healthcare Pharmaceuticals Inc.	$100	Research payment	Cash or cash equivalent	Non-Covered	BAY 94-8862 ph 3 conventional in diab nephropathy	2019
2019-12-11	GlaxoSmithKline, LLC.	$76,800	Research payment	Cash or cash equivalent			2019
2019-12-11	Lundbeck LLC	$35,122	Research payment	Cash or cash equivalent	NORTHERA Drug, NEUROLOGY	Clinical Diagnosis of Neurogenic Orthostatic Hypotension	2019
2019-12-11	Genentech, Inc.	$32,319	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	OPEN LABEL EXTENSION	2019
2019-12-11	Regeneron Pharmaceuticals, Inc.	$19,639	Research payment	Cash or cash equivalent		A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC	2019
2019-12-11	ABBVIE INC.	$6,238	Research payment	Cash or cash equivalent		M15-562	2019
2019-12-11	E.R. Squibb & Sons, L.L.C.	$6,190	Research payment	Cash or cash equivalent	OPDIVO Biological, Oncology	Phase III 1L GBM Unmethylated MGMT nivo mono RT	2019
2019-12-11	ABBVIE INC.	$2,625	Research payment	Cash or cash equivalent		M15-563	2019
2019-12-11	Genentech, Inc.	$2,384	Research payment	Cash or cash equivalent	Alecensa Biological, BioOncology	MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT T	2019
2019-12-11	Medical Device Business Services, Inc.	$2,000	Grant	Cash or cash equivalent	ANSPACH Device, Power Tools		2019
2019-12-11	ABBVIE INC.	$1,000	Research payment	Cash or cash equivalent		M15-563	2019
2019-12-11	PFIZER INC.	$557	Research payment	Cash or cash equivalent	XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT	A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	2019
2019-12-11	GENZYME CORPORATION	$475	Research payment	Cash or cash equivalent	LEMTRADA Drug, MULTIPLE SCLEROSIS	A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profi	2019
2019-12-11	ABBVIE INC.	$118	Research payment	Cash or cash equivalent		M15-563	2019
2019-12-10	Ultragenyx Pharmaceutical Inc.	$24,893	Research payment	Cash or cash equivalent		UX023-CL401	2019
2019-12-10	Kite Pharma, Inc.	$16,109	Research payment	Cash or cash equivalent		A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphom	2019
2019-12-10	AstraZeneca Pharmaceuticals LP	$5,109	Research payment	Cash or cash equivalent	FARXIGA Drug, Cardiovascular and Metabolism	Forxiga HF-D1699C00001 HF rEF Outcome study	2019
2019-12-10	Octapharma USA, Inc.	$2,000	Research payment	Cash or cash equivalent	OCTAPLAS Biological, INTENSIVE CAREEMERGENCY	LAS-215	2019
2019-12-10	ABBVIE INC.	$1,613	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-533	2019
2019-12-10	ABBVIE INC.	$1,613	Research payment	Cash or cash equivalent	Skyrizi Biological, Immunology	M15-991	2019
2019-12-10	ABBVIE INC.	$1,500	Research payment	Cash or cash equivalent		M16-135	2019
2019-12-10	ABBVIE INC.	$1,500	Research payment	Cash or cash equivalent	Skyrizi Biological, Immunology	M16-067	2019
2019-12-10	ABBVIE INC.	$1,500	Research payment	Cash or cash equivalent	Rinvoq Biological, Immunology	M14-234	2019
2019-12-10	AstraZeneca Pharmaceuticals LP	$1,395	Research payment	Cash or cash equivalent	LYNPARZA Drug, Oncology	Study of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration Resistant Prosta	2019
2019-12-10	AstraZeneca UK Limited	$1,037	Research payment	Cash or cash equivalent	BYDUREON Drug, Cardiovascular and Metabolism	A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O	2019
2019-12-09	Bayer Healthcare Pharmaceuticals Inc.	$10,727	Research payment	Cash or cash equivalent	Non-Covered	DHODH Ph1 FIM DE AML MDS with 2 ARM Expansion	2019
2019-12-09	Bayer Healthcare Pharmaceuticals Inc.	$10,210	Research payment	Cash or cash equivalent	Non-Covered	DHODH Ph1 FIM DE AML MDS with 2 ARM Expansion	2019
2019-12-09	Bayer Healthcare Pharmaceuticals Inc.	$5,775	Research payment	Cash or cash equivalent	Non-Covered	DHODH Ph1 FIM DE AML MDS with 2 ARM Expansion	2019
2019-12-09	Bayer Healthcare Pharmaceuticals Inc.	$3,362	Research payment	Cash or cash equivalent	Non-Covered	DHODH Ph1 FIM DE AML MDS with 2 ARM Expansion	2019
2019-12-09	Bayer Healthcare Pharmaceuticals Inc.	$3,352	Research payment	Cash or cash equivalent	Non-Covered	DHODH Ph1 FIM DE AML MDS with 2 ARM Expansion	2019
2019-12-09	Gilead Sciences, Inc.	$1,500	Research payment	Cash or cash equivalent		Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib	2019
2019-12-07	Merck Sharp & Dohme LLC	$990,028	Research payment	Cash or cash equivalent	V114 Biological, VACCINE	Hospitalized pneumococcal community acquired pneumonia in adults - US	2019
2019-12-07	Genentech, Inc.	$132,636	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	ASO HTT PIVOTAL TRIAL	2019
2019-12-07	Merck Sharp & Dohme LLC	$104,613	Research payment	Cash or cash equivalent	V114 Biological, VACCINE	Hospitalized pneumococcal community acquired pneumonia in adults - US	2019
2019-12-07	Merck Sharp & Dohme LLC	$500	Research payment	Cash or cash equivalent	V114 Biological, VACCINE	Hospitalized pneumococcal community acquired pneumonia in adults - US	2019
2019-12-06	AXOGEN	$41,254	Research payment	Cash or cash equivalent		Registry of Avance Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction RANGER	2019
2019-12-06	W. L. Gore & Associates, Inc.	$8,675	Research payment	Cash or cash equivalent	Product in Development Device, Devices	Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms	2019
2019-12-06	Alnylam Pharmaceuticals Inc.	$3,148	Research payment	Cash or cash equivalent	ONPATTRO Drug, Genetic Disease	Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis hATTR	2019
2019-12-06	W. L. Gore & Associates, Inc.	$1,500	Research payment	Cash or cash equivalent	Product in Development Device, Devices	GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P	2019
2019-12-06	Mallinckrodt Enterprises LLC	$1,246	Research payment	Cash or cash equivalent		A MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY	2019
2019-12-06	Merck Sharp & Dohme LLC	$55	Research payment	In-kind items and services	ZINPLAVA Biological, INFECTIOUS DISEASE	Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar	2019
2019-12-06	Abbott Laboratories	$21	Research payment	In-kind items and services	HeartMate II LVAS Device, Cardiac Arrhythmias and Heart Failure	HM3 SWIFT Study	2019
2019-12-06	Novo Nordisk AS	$12	Research payment	In-kind items and services	REBINYN Drug, Hemophilia	NN7999-3895	2019
2019-12-06	Novo Nordisk AS	$9	Research payment	In-kind items and services	REBINYN Drug, Hemophilia	NN7999-3895	2019
2019-12-06	Novo Nordisk AS	$8	Research payment	In-kind items and services	REBINYN Drug, Hemophilia	NN7999-3895	2019
2019-12-06	Novo Nordisk AS	$7	Research payment	In-kind items and services	REBINYN Drug, Hemophilia	NN7999-3895	2019
2019-12-06	Novo Nordisk AS	$4	Research payment	In-kind items and services	REBINYN Drug, Hemophilia	NN7999-3895	2019
2019-12-06	Novo Nordisk AS	$3	Research payment	In-kind items and services	REBINYN Drug, Hemophilia	NN7999-3895	2019
2019-12-05	BioMarin Pharmaceutical Inc.	$15,614	Research payment	Cash or cash equivalent		A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in	2019
2019-12-05	Intercept Pharmaceuticals, Inc.	$12,966	Research payment	Cash or cash equivalent		1009742	2019
2019-12-05	PFIZER INC.	$6,638	Research payment	Cash or cash equivalent	BAVENCIO Drug, ONCOLOGY	A RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY CISPLATIN PLUS	2019
2019-12-05	Travere Therapeutics, Inc.	$3,000	Research payment	Cash or cash equivalent	(820) Cholbam Drug, Hepatology	The Replace Registry	2019
2019-12-05	Novo Nordisk AS	$3,000	Research payment	Cash or cash equivalent		NN9535-4352	2019
2019-12-05	Novocure Inc.	$2,345	Research payment	Cash or cash equivalent	Optune Device, Oncology	EF-25 Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 b	2019
2019-12-05	Travere Therapeutics, Inc.	$2,154	Research payment	Cash or cash equivalent	(820) Cholbam Drug, Hepatology	The Replace Registry	2019
2019-12-05	Travere Therapeutics, Inc.	$2,059	Research payment	Cash or cash equivalent	(820) Cholbam Drug, Hepatology	The Replace Registry	2019
2019-12-05	Spiration, Inc.	$2,000	Research payment	Cash or cash equivalent	Spiration Valve System Device, EndoTherapy Products	A Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val	2019
2019-12-05	Pharmacyclics LLC, an AbbVie Company	$1,609	Research payment	Cash or cash equivalent	Ibrutinib Drug, Oncology	PCYC-1128-CA	2019
2019-12-05	Genentech, Inc.	$1,609	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS	2019
2019-12-05	Merck Sharp & Dohme LLC	$880	Research payment	Cash or cash equivalent			2019
2019-12-05	Spiration, Inc.	$845	Research payment	Cash or cash equivalent	Spiration Valve System Device, EndoTherapy Products	A Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val	2019
2019-12-05	Pharmacyclics LLC, an AbbVie Company	$775	Research payment	Cash or cash equivalent	Ibrutinib Drug, Oncology	PCYC-1128-CA	2019
2019-12-04	Genentech, Inc.	$490,000	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	GENETIC ANALYSIS OF THE VALID COHORT OF ARDS AND SEPSIS PATIENTS	2019
2019-12-04	PFIZER INC.	$21,295	Research payment	Cash or cash equivalent		FIP STUDY FOR PRMT5	2019
2019-12-04	Medtronic Vascular, Inc.	$8,738	Research payment	Cash or cash equivalent	HeartWare HVAD Device, Ventricular Assist Devices	PSR-MCS	2019

The latest 200 records of 3,129.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Nashville-Davidson, TN, county Davidson County, TN, state Tennessee; placed by its city name.

Measure	Place (city or town) Nashville-Davidson, TN	County Davidson County, TN	State Tennessee
Population B01003	690,130	715,388	7,066,383
Population, 2020 census P1	689,447	715,884	6,910,840
Median age B01002	34.5	34.6	38.9
Under 18 B01001	20.7%	20.7%	22.2%
65 and over B01001	12.7%	12.9%	17.1%
Households B11001	313,513	324,907	2,824,277
Foreign born B05002	15.3%	15.0%	6.1%
Median household income B19013	$77,371	$77,853	$69,595
Median family income B19113	$98,376	$99,460	$87,314
Per capita income B19301	$49,061	$50,640	$39,437
Poverty rate B17001	14.1%	13.9%	13.8%
Unemployment rate B23025	4.5%	4.5%	4.7%
Civilian labor force B23025	407,433	421,061	3,527,571
Mean commute (minutes) B08013	24.7	24.7	25.7
Bachelor's degree or higher B15003	48.0%	48.4%	31.1%
Housing units B25001	344,794	357,113	3,143,670
Owner-occupied B25003	52.4%	52.8%	66.9%
Renters B25003	47.6%	47.2%	33.1%
Median home value B25077	$413,600	$417,400	$286,700
Median gross rent B25064	$1,586	$1,582	$1,189
White, not Hispanic B03002	52.6%	53.2%	71.0%
Black B03002	24.5%	24.3%	15.4%
Hispanic or Latino B03002	14.1%	13.9%	7.4%
Asian B03002	3.5%	3.4%	1.9%
American Indian and Alaska Native B03002	0.1%	0.1%	0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Nashville-Davidson, TN.